(Q44710801)

5 December 2017

title

Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals (English)

1 reference

5 December 2017

Jun-Sheng Wang

1

1 reference

5 December 2017

Robin Taylor

2

1 reference

5 December 2017

Ying Ruan

3

1 reference

5 December 2017

Jennifer L Donovan

4

1 reference

5 December 2017

John S Markowitz

5

1 reference

5 December 2017

C Lindsay De Vane

6

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

5 December 2017

published in

Neuropsychopharmacology

1 reference

5 December 2017

volume

29

1 reference

5 December 2017

issue

3

1 reference

5 December 2017

page(s)

551-557

1 reference

Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Olanzapine: an updated review of its use in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

The human ATP-binding cassette (ABC) transporter superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

An evaluation of risperidone drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

P-glycoprotein--a mediator of multidrug resistance in tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

St Johns wort increases expression of P-glycoprotein: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Role of P-glycoprotein in pharmacokinetics: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

7 January 2021

A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

7 January 2021

Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

7 January 2021

Identification of P450 enzymes involved in metabolism of verapamil in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300372

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300372

1 reference

Dimensions Publication ID

5 December 2017

1024438894

0 references

1 reference